



**ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

(Stock Code: 1061)

**Change of Company Logo Represents a Transformation for  
Essex Bio-Technology**

***Pioneering Global Regenerative Science & Technology***

Hong Kong, 28 February 2018 — — ESSEX BIO-TECHNOLOGY LIMITED (“EssexBio” or the “Company”—Stock code: 1061) is pleased to announce that the Company’s logo has been changed with effect from 28 February 2018. The Company’s old and new logos are set out below for identification purpose:



(old logo)



(new logo)

The Company’s new logo represents a transformation for EssexBio, evolving into a new development horizon, *pioneering global regenerative science & technology*.

The dominant colors of blue & green and the design together represent the corporate characteristics of EssexBio as being dynamic, creative, and visionary. The corporate characteristics of EssexBio are built upon the corporate culture of EssexBio -- the sense of responsibility, urgency and belonging, and being innovative and cooperative. Leveraging on the Company’s internal strengths, EssexBio strives consistently to achieve its core value in delivering unmet drugs for blessing of people at large.

In the past years, EssexBio has established a comprehensive internal capability and capacity to develop, manufacture and commercialise genetically engineered therapeutic rb-bFGF, and thus built its core competence of bio-pharmaceuticals in the field of Ophthalmology and Dermatology. Furthermore, the Enrichment

Program initiated since 2015 enables the Company to expand into new markets of Stomatology, Obstetrics & Gynaecology, Neurology, Oncology and Orthopaedics.

Under the Enrichment Program, the Company proactively seeks to invest in and forge strategic alliance with companies, in the People's Republic of China (the "PRC") and overseas, having first-in-class, novel bio-pharmaceutical projects at various stages of research and development and clinical program primarily in ophthalmology, stomatology, oncology and neurology. To-date, a total of approximately US\$24.7 million has been invested in a total of 7 entities; such as AC Immune SA, Abpro Corporation and MeiraGTx Limited.

The investments as a whole would complement EssexBio's research and development and as enablers to advance its ambition to expand and build new strengths within the company. Evidently, the knowledge of EssexBio in protein engineering and specifically in fibroblasts growth factors (FGF) will be expanded in new fields of neurology through the investment and R&D collaboration with AC Immune whilst the investment in Abpro will allow Essex to leapfrog its peers and enter into immuno-therapy in the field of Oncology and Ophthalmology.

*Tomorrow's today*, the new future is emerging; EssexBio is pragmatically moving forward to creating greater and sustainable economic and social values for all stakeholders.

### **About EssexBio**

Essex Bio-Technology Limited is a bio-pharmaceutical company, started in early 90's, a pioneer in bio-pharmaceutical industry in China, that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF, a basic fibroblast growth factor, with established mechanism of action in cellular proliferation, differentiation and migration.

The Company currently has five commercialised bio-pharmaceutical products, formulated with rb-bFGF, in China, out of which 3 are approved by CFDA as Category I drugs. The products are being marketed & sold as Beifushu, Beifuji & Beifuxin, for treatment of ocular surface wounds and topical (skin) surface wounds respectively. Beifuji is the first in the world to have obtained approval from CFDA for commercialisation in 1998.

The Company focuses on two main therapeutics: Ophthalmology and Surgical arena of topical (skin) surface wounds, which primarily covers Dermatology, Stomatology and Obstetrics & Gynaecology, while selectively pursuing therapeutics in Neurology, Oncology and Orthopaedics. The Company maintains a pipeline of multi-project in R&D and on various stages of clinical programs, of which several projects involving growth factors and antibody and a handful of

projects are on unit dose for Ophthalmology and Respiratory.

The Company's products and its 3rd party products are marketed and sold through more than 5, 400 hospitals in China and are managed directly by its 39 regional sales offices with more than 1,410 sales and marketing people. Its 3rd party products; notably are inclusive of Xalacom and Xalatan of Pfizer (for Ophthalmology), Iodized Lecithin Capsules (for Ophthalmology), Yi Xue An Granules (for Obstetrics & Gynaecology) and Carisolv Products (for Stomatology).

This press release is issued by Zhixin Investor Relations Consultant Limited on behalf of **Essex Bio-Technology Limited**.

For further information, please contact:

Zhixin Investor Relations Consultant Limited

Ms. Tan Ronghua

Tel: 0755 8323 9767

E-mail: [tanronghua@zhixincaijing.com](mailto:tanronghua@zhixincaijing.com)